

Topical Corticosteroids

Selected References:

- Andersson NW et al 2021. Evaluation of topical corticosteroids use in pregnancy and risk of newborns being small for gestational age and having low birth weight. JAMA Dermatol 157(7): 788-795. Doi10.1001/jamadermatol.2021.1090.
- Chan TC, et al. 2020. Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update. Journal of the Formosan Medical Association.
- Chi CC et al. 2013. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatol. 149(11):1274-1280.
- Chi CC, et al. 2015. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. (10):CD007346.
- Chi CC, et al. 2016. Safety of Topical Corticosteroids in Pregnancy. JAMA Dermatol. 152(8):934-5.
- Chi CC, et al. 2017. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. J Eur Acad Dermatol Venereol. 31(5):761-773.
- Hamann CR, et al. 2018. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. J Eur Acad Dermatol Venereol. [Epub ahead of print].
- Mygind H et al 2002. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid pregnancy. Acta Obstet Gynecol Scand 81(3):234-239.
- Stacey SK, McEleney M. 2021. Topical Corticosteroids: Choice and Application. Am Fam Physician; 103(6):337-343.
- Tyler KH. 2015. Dermatologic therapy in pregnancy. Clin Obstet Gynecol. 58(1):112-8.
- Vestergaard C, et al. 2019. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 33(9): 1644-1659

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Topical Corticosteroids

Selected References:

- Atmar RL, et al. 1992. Complications of measles during pregnancy. *Clin Infect Dis*; 14(1):217-26.
- American Academy of Pediatrics (AAP). 2024. Red Book: 2024-2027 Report of the Committee on Infectious Diseases. Measles. pp 571 – 585.
- AAP. 2026. Red Book Online Outbreaks: Measles. Available at: <https://publications.aap.org/redbook/resources/pdfDownload/15187>. Accessed March 2026.
- Bloch AB, et al. 1985. Measles outbreak in a pediatric practice: airborne transmission in an office setting. *Pediatrics*; 75(4):676-83.
- Casalegno JS, et al. 2014. Measles in pregnancy in Lyon France, 2011. *Int J Gynaecol Obstet*; 126(3):248-51.
- Chen, W, et al. 2004. No evidence for links between autism, MMR, and measles virus. *Psychol Med* 34:543-553.
- Chiba ME, et al. 2003. Measles infection in pregnancy. *J Infect*; 47(1):40-4.
- Congera P, et al. 202. Measles in pregnant women: A systematic review of clinical outcomes and a meta-analysis of antibodies seroprevalence. *J Infect*; 80(2):152-160.
- Crecelius EM, Burnett MW. 2020. Measles (Rubeola): An Update. *J Spec Oper Med*; 20(2):136-138.
- Eberhart-Phillips JE, et al. 1993. Measles in pregnancy: a descriptive study of 58 cases. *Obstet Gynecol*; 82(5):797-801.
- Khalil A, et al. 2024. Pregnant women and measles: we need to be vigilant during outbreaks. *EClinicalMedicine*; 72:102594.
- Liang Q, et al. 2016. The influence of maternal exposure history to virus and medicine during pregnancy on congenital heart defects of fetus. *Environ Sci Pollut Res Int*; 24(6):5628-5632.
- Garg RK, et al. 2023. Obstetric outcomes in pregnant women with subacute sclerosing panencephalitis (SSPE): a systematic review of case reports and case series. *Neurol Sci*; 44(6):1959-1968.
- Jespersen CS, et al. 1977. Measles as a cause of fetal defects: a retrospective study of ten measles epidemics in Greenland. *Acta Paediatr Scand*; 66:367-78.
- Moss WJ. 2017. Measles. *Lancet*. 390(10111):2490-2502.
- Ogbuanu IU, et al. 2014. Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009-2010. *Clin Infect Dis*; 58(8):1086-92.
- Rosa C. 1998. Rubella and rubeola. *Semin Perinatol*; 22(4):318-22.
- Siegel M, Fuerst HT. 1966. Low birth weight and maternal virus diseases. A prospective study of rubella, measles, mumps, chickenpox, and hepatitis. *JAMA*; 197(9):680-4.
- Signore C. 2001. Rubeola. *Prim Care Update Ob Gyns*; 8(4):138-140.
- Stein SJ, Greenspoon JS. 1991. Rubeola during pregnancy. *Obstet Gynecol*; 78(5 Pt 2):925-9.
- Stoneman EK. 2025. Measles. *JAMA*; doi: 10.1001/jama.2025.14210.
- The Centers for Disease Control and Prevention. (CDC) 2019. Measles (Rubeola). <https://www.cdc.gov/measles/>. Accessed March 2026.
- The Centers for Disease Control and Prevention (CDC). 2021. Epidemiology and Prevention of Vaccine-Preventable Diseases, Chapter 13: Measles. Available at <https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-13-measles.html>. Accessed March 2026.
- Vega JS, et al, CDC. 2014. Notes from the field: measles transmission at a domestic terminal gate in an international airport – United States, January 2014. *MMWR Morb Mortal Wkly Rep*; 63(50):1211.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Topical Corticosteroids

Selected References:

- Anderson KN, et al. 2020. ADHD medication use during pregnancy and risk for selected birth defects: national birth defects prevention study, 1998-2011. *J Atten Disord*, 24(3):479-489.
- Bang Madsen K., et al. 2025. In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders – a population-based cohort study and meta-analysis. *Molecular psychiatry*, 30(9), 3885–3894.
- Benassayag Kaduri N, et al. 2024. Amphetamine use for attention deficit hyperactive disorder during breastfeeding and children's neurodevelopmental outcomes: A pilot study. *Psychiatry research*, 339, 116047.
- Cohen JM, et al. 2017. Placental complications associated with psychostimulant use in pregnancy. *Obstet Gynecol*, 130(6):1192-1201.
- Golub M, et al. 2005. NTP CERHR expert panel report on the reproductive and developmental toxicity of amphetamine and methamphetamine. *Birth Defects Res B Dev Reprod Toxicol*, 74(6):471-584.
- Hasan SA, et al., 2026. Prescription Stimulant Continuation in Pregnancy and Birth Outcomes. *Journal of attention disorders*, 30(3), 315–328.
- Huybrechts KF, et al. 2018. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. *JAMA Psychiatry*, 75(2):167-175.
- Ilett KF, et al. 2007. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. *Br J Clin Pharmacol*, 63(3):371-375.
- Naeye RL, 1983. Maternal use of dextroamphetamine and growth of the fetus. *Pharmacology*, 26(2):117-120.
- Newport DJ, et al. 2016. Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy. *J Clin Psychiatry*. 77(11):1538-45.
- Norby U et al. 2017. Perinatal outcomes after treatment with ADHD medication during pregnancy. *Pediatrics* 140(6).
- Ornoy A, 2018. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. *Pharm Res*, 35:46
- Öhman I, et al. 2015. Narcolepsy treated with racemic amphetamine during pregnancy and breastfeeding. *J Hum Lact* 31:374-6.

- Pham MN, et al. 2022. The adverse association between stimulant use for attention deficit hyperactivity disorder (ADHD) and semen parameters. *Andrologia*, 54(2), e14315.
- Poulton AS et al. 2018. Perinatal outcomes of women diagnosed with attention-deficit/hyperactivity disorder: An Australian population-based cohort study. *CNS Drugs* 32(4):377-386.
- Rastegar-Pouyani N., et al. 2025. Prenatal Exposure to Methamphetamine and Its Association With Birth Outcomes: A Meta-Analysis. *Birth defects research*, 117(7), e2488
- Rose SJ, et al., 2020. Amphetamine-dextroamphetamine and pregnancy: neonatal outcomes after prenatal prescription mixed amphetamine exposure. *Journal of Attention Disorders*, 25(9):1295-1301.
- Russell DJ, et al. 2024. Investigating maternal and neonatal health outcomes associated with continuing or ceasing dexamphetamine treatment for women with attention-deficit hyperactivity disorder during pregnancy: a retrospective cohort study. *Arch Womens Ment Health*; 27(5):785-794.
- Srinivas C, et al. 2025. Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage. *The British journal of psychiatry: the journal of mental science*, 1-7.
- Srinivas, C, et al. 2025. Attention-Deficit/Hyperactivity Disorder Medication Use in Pregnancy and Risk of Preterm Birth: A Population-Based Cohort Study. *Paediatric and perinatal epidemiology*, 10.1111/ppe.70031.
- Suarez EA, et al. 2024. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. *JAMA psychiatry*, 81(5), 477-488.
- U.S. Food and Drug Administration. 2017. Vyvanse® (lisdexamfetamine dimesylate). [Accessed 3/2026]. from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Topical Corticosteroids

Selected References:

- Centers for Disease Control and Prevention. 2025. About RSV. Available at <https://www.cdc.gov/rsv/about/index.html>. Accessed 4 March 2026.
- Centers for Disease Control and Prevention. 2024. RSV Vaccine Guidance for Pregnant Women. Available at <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html>. Accessed 4 March 2026.
- DeSilva M. 2025. Prenatal RSVpreF Vaccine Safety 2023–2024 Respiratory Season: The Vaccine Safety Datalink (VSD). Centers for Disease Control and Prevention. Presented at: Meeting of the Advisory Committee on Immunization Practices (ACIP); June 25, 2025; Atlanta, Georgia. Available at: <https://www.cdc.gov/acip/downloads/slides-2025-06-25-26/04a-DeSilva-Mat-Peds-RSV-508.pdf>. Accessed 4 March 2026.
- Fleming-Dutra KE, et al. 2023. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. *MMWR Morb Mortal Wkly Rep*; 72(41):1115-1122.
- Kampmann B, et al. 2023. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. *N Engl J Med*; 388:1451-146.
- Marchand GJ, et al. 2024. RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy. *Obstet Gynecol Sci* 67(6): 511-524.
- Michnick AI, et al. 2026. Interim safety of RSVpreF vaccination during pregnancy. *JAMA*. 335(5):456–459.
- U.S. Food and Drug Administration. 2023 (Revised 2025). Abrysvo™ Prescribing Information. Available at: <https://www.fda.gov/media/168889/download>. Accessed 4 March 2026.
- Son M, et al. 2024. Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes. *JAMA Netw Open*; 7(7):e2419268.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Topical Corticosteroids

Selected References:

- Anderson PO. 2021. Monoclonal antibodies during breastfeeding. *Breastfeed Med*; 16(8):591-593.
- Jang W, et al. 2025. Use of biologics to treat asthma during pregnancy and adverse events in pregnant women and newborns: A global pharmacovigilance analysis. *Int Arch Allergy Immunol*; 186(9):875-888.
- Kasuya A, et al. 2019. Successful control of severe eosinophilic granulomatosis with polyangiitis in pregnancy and perinatal period: A use of mepolizumab. *The Journal of Dermatology*; 46(9):e309-e311.
- Marques Simões J, et al. 2026. Safety and Efficacy of Mepolizumab during Pregnancy and Postpartum. *Acta Med Port*; 39(3):239-240.
- Nucala® Prescribing Information. Revised 1/2022. Available online at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IF U-COMBINED.PDF.
- Ramos CL, Namazy J. 2023. Monoclonal antibodies (biologics) for allergic rhinitis, asthma, and atopic dermatitis during pregnancy and lactation. *Immunol Allergy Clin North Am*; 43(1):187-197.
- Shakuntulla F, Chiarella SE. 2022. Safety of biologics for atopic diseases during pregnancy. *J Allergy Clin Immunol Pract*; 10(12):3149-3155.
- Sitek AN, et al. 2023. Risks and safety of biologics: A practical guide for allergists. *World Allergy Organ J*; 16(1):100737.
- Smith DA, et al. 2011. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. *Clin Pharmacokinet*; 50(4):215-227.
- Vittorakis SK, et al. 2022. Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy. *Respir Med Case Rep*; 28;41:101785.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.